Alteogen Inc
KOSDAQ:196170
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
67 800
445 500
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alteogen Inc
Alteogen Inc
Retained Earnings
Alteogen Inc
Retained Earnings Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alteogen Inc
KOSDAQ:196170
|
Retained Earnings
₩23.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Retained Earnings
₩4T
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Retained Earnings
₩549.4B
|
CAGR 3-Years
118%
|
CAGR 5-Years
127%
|
CAGR 10-Years
N/A
|
|
|
Green Cross Corp
KRX:006280
|
Retained Earnings
₩856.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Retained Earnings
₩1T
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Retained Earnings
₩299.7B
|
CAGR 3-Years
32%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Alteogen Inc
Glance View
Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.
See Also
What is Alteogen Inc's Retained Earnings?
Retained Earnings
23.4B
KRW
Based on the financial report for Sep 30, 2024, Alteogen Inc's Retained Earnings amounts to 23.4B KRW.
What is Alteogen Inc's Retained Earnings growth rate?
Retained Earnings CAGR 1Y
-11%
Over the last year, the Retained Earnings growth was -11%.
You don't have any saved screeners yet
